Bortezomib, a new treatment for malignant mesothelioma and myeloma, shows promising future amongst cancer research.
The discovery of the BAP1 mutation in mesothelioma has allowed researchers to expand knowledge on how to improve survival rates.
The International Mesothelioma Program is a center for mesothelioma at the Brigham and Women’s Hospital in Boston, Massachusetts.
International Symposium on Malignant Mesothelioma, hosted by the Mesothelioma Applied Research Foundation, will be held July 22-23 of 2022.
The combination of CT imaging features with a history of asbestos exposure may be key information to diagnose pleural mesothelioma.
A non-invasive treatment that combines chemotherapy with electrical currents to shrink mesothelioma tumors appear to be working for patients.
The phase II OT-101 clinical trial will study a promising treatment option for patients with pleural mesothelioma.
Mesothelioma clinical trials work to advance treatment for patients. Learn more about 5 current mesothelioma clinical trials.
Researchers have developed targeted treatment with heat-activated gold spheres (nanotubes) to help with killing mesothelioma tumors.
An anticipated new mesothelioma clinical trial involving a novel drug, RSO-021, will take place at the University of Vermont Cancer Center.